Discovery of 6-chloro-2-trifluoromethyl-7-aryl-7H-imidazo[1,2-a]imidazol-3-ylmethylamines, a novel class of corticotropin-releasing factor receptor type 1 (CRF1R) antagonists
作者:Dmitry Zuev、Vivekananda M. Vrudhula、Jodi A. Michne、Bireshwar Dasgupta、Sokhom S. Pin、Xiaohua Stella Huang、Dedong Wu、Qi Gao、Jie Zhang、Matthew T. Taber、John E. Macor、Gene M. Dubowchik
DOI:10.1016/j.bmcl.2010.04.094
日期:2010.6
A novel series of [6-chloro-2-trifluoromethyl-7-aryl-7H-imidazo[1,2-a]imidazol-3-ylmethyl]-dialkylamines was discovered as potent CRF1R antagonists. The optimization of binding affinity in the series by the parallel reaction approach is discussed herein. (c) 2010 Elsevier Ltd. All rights reserved.
[EN] COMPOUNDS THAT INHIBIT MCL-1 PROTEIN<br/>[FR] COMPOSÉS INHIBANT LA PROTÉINE MCL-1
申请人:AMGEN INC
公开号:WO2017147410A1
公开(公告)日:2017-08-31
Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.